Imexpharm Corporation announces the Board resolution dated February 13, 2020 as follows:
Article 1: Approving the report on business performance in 2019:
No.
|
Item
(VND billion)
|
Reality in 2019
|
Compared to plan 2019
|
Growth rate
|
1
|
Net revenue and income
|
1,420.7
|
98.0%
|
17.7%
|
2
|
Profit before tax and before distributing to Science and Technology Fund
|
222.4
|
101.1%
|
15.4%
|
3
|
Profit before tax
|
202.4
|
|
16.5%
|
Article 2: Approving the report on business plan for 2020:
No.
|
Item
(VND billion)
|
Target for 2020
|
Growth rate
|
1
|
Net revenue and income
|
1,750.0
|
23.2%
|
2
|
Profit before tax and before distributing to Science and Technology Fund
|
260.0
|
16.9%
|
3
|
Profit before tax
|
260.0
|
28 4%
|
Article 3: Approving the report on the progress of Binh Duong High-Tech Plant (IMP4) until December 31, 2019. The plant is expected to be reviewed EU-GMP standards by the end of the quarter of 2020.
Article 4: Approving to authorize the CEO to receive credit limits at commercial banks in 2020 with the total limit of VND300 billion.
Article 5: Approving the wage unit, the reward regulation in 2019.
Article 6: Approving the treatment of doubtful debts with the total value of VND23,534,146.
Article 7: Approving the record date to convene the 2020 Annual General Meeting of Shareholders:
- Estimated meeting date: April 17, 2020
- Estimated record date: March 18, 2020
- Estimated meeting venue: Head office of Imexpharm, No.04 Street 30/4, Cao Lanh city, Dong Thap province.
Article 8: Approving the agenda and documents of the 2020 Annual General Meeting of Shareholders.
- Document on the establishment of sub-boards under the Board of Directors;
- Document on the amendment of Company’s Charter;
- Document on the amendment of internal governance regulations;
- Report on expenses of the Board of Directors and Board of Supervisors in 2019;
- Plan for expenses of the Board of Directors and Board of Supervisors in 2020;
- Profit distribution plan for 2019 and dividend plan for 2020;
- Stock issue plan for capital increase in 2020.